Plozasiran
Tracked across 1 events · 6 articles · First seen May 26, 2026 · Last active May 26, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Arrowhead Pharmaceuticals presented new positive clinical data for Plozasiran at the 94th European Atherosclerosis Society Congress. The data support the use of Plozasiran in patients with moderate-to-severe renal impairment or moderate hepatic impairment without dose…
Impact: Plozasiran, an siRNA medicine, showed positive clinical data for use in patients with renal or hepatic impairment without dose adjustment and sustained triglyceride lowering during pregnancy, expanding its potential patient population and market.
May 26, 2026 · 6 articles
90
Plozasiran supported useArrowhead Presents...
80
Plozasiran associated with loweringArrowhead Presents...
70
European Union — European Medicines Agency adopted positive opinion PlozasiranArrowhead Presents...
60
United States — Food and Drug Administration granted Breakthrough Therapy PlozasiranArrowhead Presents...
NEWSDESK
Track Plozasiran live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard